

Emmaus Life Sciences, Inc.

Amendment to [Management Certification](#) for 12/31/2025 originally published through the OTC Disclosure & News Service on 04/02/2026

Explanatory Note:

Added control persons for two entities

***This coversheet was automatically generated by OTC Markets Group based on the information provided by the Company. OTC Markets Group has not reviewed the contents of this amendment and disclaims all responsibility for the information contained herein.*

Management Certification

The undersigned, on behalf of Emmaus Life Sciences, Inc. ("the Company"), certifies that the information provided herein is accurate and complete to the best of the Company's knowledge.

1. The Company is current in its disclosure obligations pursuant to the following reporting standard:

SEC Reporting Obligations

- The Company has a reporting obligation under Section 13 or 15(d) of the Exchange Act
- The Company has a reporting obligation under Regulation A (Tier 2)
- The Company has a reporting obligation under Regulation Crowdfunding (CF)
- Other (please describe)

Other Reporting Obligations

- The Company is a U.S. bank, bank holding company, or similar financial institution exempt from SEC registration, has a reporting obligation to a U.S. Bank Regulator and follows OTC Markets' Bank Reporting requirements.
- The Company is exempt from SEC registration and is reporting under the Alternative Reporting Standard
2. Indicate below whether the Company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

3. Indicate below whether the Company is subject to Bankruptcy or reorganization proceedings.

Yes: No:

4. The Company has a Verified Company Profile on OTCMarkets.com.
5. The Company is duly organized and in good standing under the laws of the state or jurisdiction in which the Company is organized or does business.
6. The Company understands and acknowledges its obligations to report company-related actions pursuant to Exchange Act Rule 10b-17 and FINRA Rule 6490.
7. The Company understands and acknowledges its obligations to publicly disclose material information in a timely manner in accordance with applicable U.S. federal securities laws, including but not limited to Section 10(b) of the Exchange Act and Rule 10b-5 thereunder.
8. The Company's transfer agent and its address are listed below. If the Company acts as its own transfer agent, indicate that by listing the Company and its information in the fields provided.¹

Transfer Agent: Equiniti Trust Company (aka American Stock Transfer)
Address: 28 Liberty St., New York, NY 10005

¹ OTCQX, OTCQB, and OTCID companies are required to retain a transfer agent that participates in the Transfer Agent Verified Shares Program. OTCID companies that act as their own transfer agent may submit data directly to OTC Markets.

9. The Company's most recent Annual Report was prepared by:

Below is a list all law firm(s) and attorney(s) (including internal counsel) that acted as the Company's primary legal counsel in preparing its most recent annual report or, if no attorney assisted in preparing the disclosure, the person(s) who prepared the disclosure and their relationship to the Company.

Dale Short, Legal Consultant

10. The Company's Officers, Directors and 5% Control Persons are listed below:

The table below provides information regarding all officers and directors of the Company, or any person that performs a similar function, regardless of the number of shares they own. To the best of the Company's knowledge, it includes all individuals or entities beneficially owning 5% or more of any class of the issuer's equity securities. To identify holders of 5% or more, companies may obtain a recent copy of their shareholder list that includes Non-Objecting Beneficial Owners or "NOBOs." SEC Reporting companies may also research their beneficial ownership and insider transaction filings such as on Schedules 13G or 13D or on Forms 3, 4, and 5.

As of (latest practicable date): 3/20/2026

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, 5% Control person)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
Willis Lee	CEO	Torrance, CA	795,718	Common	1.1%
Willis Lee	CEO	Torrance, CA	1,015,043	Options	1.4%
Hiroko Huynh	CAO	Torrance, CA	50,000	Options	*
Charles Stark	CSO	Rancho Palos Verdes, CA	18,182	Common	*
Charles Stark	CSO	Rancho Palos Verdes, CA	100,000	Options	0.1%
Wei Peu Zen	Director	Hong Kong	6,039,031	Common	8.6%
Wei Peu Zen	Director	Hong Kong	200,000	Options	0.3%
Yutaka Niihara	5% Control Person	Rolling Hills Estates, CA	12,202,851	Common	17.4%
John Woo Lee	5% Control Entity	South Korea	6,322,692	Common	9.0%
Telcon RF Pharmaceutical (Ji Hoon Kim, CEO)	5% Control Entity	South Korea	4,147,491	Common	6.5%

Any additional material details, including conversion terms of any class of the issuer's equity securities, are below:

11. The Company has Convertible Debt as detailed below:

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion ²	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)
2/12/21	100,000	136,272	2/28/25	\$0.01 conversion	0	3,502,394	Briana Lee	Loan
2/17/21	200,000	272,547	2/28/25	\$0.01 conversion	0	3,502,394	Mee Sook Lee	Loan
2/17/21	100,000	136,273	2/28/25	\$0.01 conversion	0	3,502,394	Susie Lee	Loan
2/19/21	250,000	270,057	2/28/25	\$0.01 conversion	0	3,502,394	Brian Oum	Loan
2/22/21	300,000	341,556	2/28/25	\$0.01 conversion	0	3,502,394	Yoon Taik Kwon	Loan
2/23/21	200,000	244,045	2/28/25	\$0.01 conversion	0	3,502,394	Mijin Lee	Loan
2/23/21	250,000	269,979	2/28/25	\$0.01 conversion	0	3,502,394	Sung Jun Oum	Loan
2/24/21	3,000,000	3,657,833	2/28/25	\$0.01 conversion	0	3,502,394	Dong Kwan Kim	Loan
2/24/21	3,000,000	1,250,633	2/28/25	\$0.01 conversion	6,322,692	3,502,394	Dong Seon Kim	Loan
2/24/21	3,000,000	3,657,833	2/28/25	\$0.01 conversion	0	3,502,394	Dong Won Kim	Loan
3/3/21	500,000	239,740	2/28/25	\$0.01 conversion	0	3,502,394	Yoon Min Park	Loan
3/26/21	1,000,000	1,127,995	2/28/25	\$0.01 conversion	0	3,502,394	Sam Jong Kim	Loan
9/5/23	1,000,000	1,395,884	On Demand	\$0.29 conversion	0	4,813,393	Smart Start Investments (Wei Peu Zen, CEO)	Loan
	12,920,000	13,000,647		Total Shares:	6,322,692	46,842,121		

Any additional material details, including footnotes to the table are below :

Signature:

² The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

Name of Principal Executive Officer or Principal Financial Officer: Willis Lee

Title: CEO

Date: 4/2/2025

Signature: /s/ Willis C. Lee

(Digital Signatures should appear as "/s/ [OFFICER NAME]")